Fulcrum Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters11-11

* Fulcrum Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on November 13 for the period ending September 30 2024

*

* LSEG's mean analyst estimate for Fulcrum Therapeutics Inc is for a loss of 41 cents per share.

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $4.00, above its last closing price of $3.49.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 0.02 -0.01 0.87 Beat 7,060

Mar. 31 2024 -0.44 -0.44 -0.43 Beat 1.7

Dec. 31 2023 -0.42 -0.43 -0.40 Beat 6

Sep. 30 2023 -0.43 -0.43 -0.39 Beat 10.3

Jun. -0.45 -0.44 -0.38 Beat 14.5

30 2023

Mar. 31 2023 -0.47 -0.46 -0.41 Beat 10

Dec. 31 2022 -0.51 -0.49 -0.50 Missed -2.1

Sep. 30 2022 -0.62 -0.61 -0.51 Beat 16.7

This summary was machine generated November 11 at 15:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482773941?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 23:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482773941","market":"us","top_or_hot":-1,"title":"Fulcrum Therapeutics Inc    expected to post a loss of 41 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> Inc     is expected to show a fall in quarterly revenue when it reports  results on November 13 for the period ending September 30 2024</p><p>   * </p><p>   * LSEG's mean analyst estimate for Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is for a loss of 41 cents per share. </p><p>   * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 5 \"hold\" and 1 \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $4.00, above its last closing price of $3.49. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  0.02        -0.01      0.87      Beat    7,060</p><p>Mar. 31 2024  -0.44       -0.44      -0.43     Beat    1.7</p><p>Dec. 31 2023  -0.42       -0.43      -0.40     Beat    6</p><p>Sep. 30 2023  -0.43       -0.43      -0.39     Beat    10.3</p><p>Jun.        -0.45       -0.44      -0.38     Beat    14.5</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.47       -0.46      -0.41     Beat    10</p><p>Dec. 31 2022  -0.51       -0.49      -0.50     Missed  -2.1</p><p>Sep. 30 2022  -0.62       -0.61      -0.51     Beat    16.7</p><p>This summary was machine generated November 11 at 15:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulcrum Therapeutics Inc    expected to post a loss of 41 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulcrum Therapeutics Inc    expected to post a loss of 41 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 23:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Fulcrum Therapeutics Inc     is expected to show a fall in quarterly revenue when it reports  results on November 13 for the period ending September 30 2024   *    * LSEG's mean analyst estimate ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FULC","symbol_name":"Fulcrum Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2482773941","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482773941","pubTimestamp":1731339514,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Fulcrum Therapeutics Inc     is expected to show a fall in quarterly revenue when it reports  results on November 13 for the period ending September 30 2024   *    * LSEG's mean analyst estimate for","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FULC":"Fulcrum Therapeutics"},"translate_title":"Fulcrum Therapeutics Inc预计每股亏损41美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":1},"content_text":"* Fulcrum Therapeutics Inc     is expected to show a fall in quarterly revenue when it reports  results on November 13 for the period ending September 30 2024   *    * LSEG's mean analyst estimate for Fulcrum Therapeutics Inc is for a loss of 41 cents per share.    * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 5 \"hold\" and 1 \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $4.00, above its last closing price of $3.49. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  0.02        -0.01      0.87      Beat    7,060Mar. 31 2024  -0.44       -0.44      -0.43     Beat    1.7Dec. 31 2023  -0.42       -0.43      -0.40     Beat    6Sep. 30 2023  -0.43       -0.43      -0.39     Beat    10.3Jun.        -0.45       -0.44      -0.38     Beat    14.530 2023                                                Mar. 31 2023  -0.47       -0.46      -0.41     Beat    10Dec. 31 2022  -0.51       -0.49      -0.50     Missed  -2.1Sep. 30 2022  -0.62       -0.61      -0.51     Beat    16.7This summary was machine generated November 11 at 15:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482773941"}